Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 11,000 | |||
2 mg | 在庫あり | ¥ 16,000 | |||
5 mg | 在庫あり | ¥ 22,500 | |||
10 mg | 在庫あり | ¥ 33,000 | |||
25 mg | 在庫あり | ¥ 59,500 | |||
50 mg | 在庫あり | ¥ 85,000 | |||
100 mg | 在庫あり | お問い合わせ | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 21,500 |
説明 | Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions. |
In vitro | TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation inhibited by Setogepram (PBI-4050; 500 μM; 24 hours). Setogepram (PBI-4050; 250 or 500 μM; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis [2]. |
In vivo | In type 2 diabetes eNOS-/-db/db mice, Setogepram (PBI-4050; 100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improve glucose tolerance [1]. |
別名 | PBI-4050, Setogepram |
分子量 | 206.28 |
分子式 | C13H18O2 |
CAS No. | 1002101-19-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (290.87 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fezagepras 1002101-19-0 Endocrinology/Hormones GPCR/G Protein GPR PBI 4050 Free Fatty Acid Receptor PBI-4050 GPR84 inhibit PBI4050 FFAR G protein coupled receptor 84 Diabetes,Kidney,Renal,Pancreatic,Liver,Fibrosis,Nephrology Inhibitor Setogepram inhibitor